Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

(2018) G Curigliano et al.   ANNALS OF ONCOLOGY

The global burden of women’s cancers: a grand challenge in global health

(2017) Ophira Ginsburg et al.   LANCET

Patient-derived xenograft (PDX) models in basic and translational breast cancer research

(2016) Lacey E. Dobrolecki et al.   CANCER AND METASTASIS REVIEWS

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response

(2016) George Sflomos et al.   CANCER CELL

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

(2016) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours

(2016) Elodie Richard et al.   JOURNAL OF PATHOLOGY

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

(2013) Otto Metzger-Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

(2010) T. O. Nielsen et al.   CLINICAL CANCER RESEARCH

The molecular pathology of breast cancer progression

(2010) Alessandro Bombonati et al.   JOURNAL OF PATHOLOGY